+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Multiple Sclerosis Market - Global Forecast 2026-2032- Product Image
Multiple Sclerosis Market - Global Forecast 2026-2032- Product Image
New

Multiple Sclerosis Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 185 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968783
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Multiple Sclerosis Market is evolving rapidly, fueled by the introduction of novel therapies, new care models, and integrated approaches to commercialization. Senior leaders face both opportunities and complexities as they seek growth and competitive positioning in this dynamic healthcare sector.

Market Snapshot: Multiple Sclerosis Market Expansion

Between 2025 and 2026, the Multiple Sclerosis Market rose from USD 16.12 billion to USD 16.81 billion. Projected forward with a CAGR of 5.30%, the market is expected to reach USD 23.14 billion by 2032. These robust growth dynamics reflect a significant transition toward more personalized medicine and expansion of the pharmaceutical landscape. The sector’s momentum is shaped by greater portfolio diversification and the emergence of new healthcare channels, driving change in both market structure and stakeholder strategy.

Scope & Segmentation: Precision-Driven Therapeutic Strategies

This comprehensive report analyzes the Multiple Sclerosis Market through a detailed segmentation and market lens, enabling targeted decision-making for stakeholders:

  • Disease Subtypes: Strategic focus addresses primary progressive, relapsing-remitting, and secondary progressive forms of MS, with nuanced clinical and operational pathways for each.
  • Therapeutic Mechanisms: Examines roles of immunomodulators, immunosuppressants, monoclonal antibodies, and sphingosine 1 phosphate receptor modulators to optimize multi-modal therapy and patient care alignment.
  • Administration Routes: Evaluates injectable, oral, and intravenous methods, analyzing their influence on adherence and prescriber decision-making across diverse care settings.
  • Distribution Pathways: Assesses hospital, online, and retail pharmacy models and their impact on supply chain logistics and reimbursement strategy design.
  • End-User Environments: Reviews how care settings such as hospitals, specialty clinics, and home-based environments shape patient engagement and therapy implementation.
  • Geographical Coverage: Includes North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America to clarify how regulatory frameworks, infrastructure, and payer models drive regional differentiation.
  • Technology Use: Explores the integration of digital health solutions, such as telehealth and remote adherence platforms, fostering scalable and data-informed patient support ecosystems.

Key Takeaways: Strategic Insights for MS Stakeholders

  • Senior decision-makers must evaluate an expanding therapeutic landscape, refining segmentation and building adherence frameworks that position their portfolio for clinical and commercial differentiation.
  • Personalized therapy strategies—aligning mechanism of action to disease subtype and patient profile—can enhance value proposition, strengthen market presence, and support improved care outcomes.
  • Adopting digital health and telemonitoring tools is essential for enabling continuity of care and measurable improvement in patient adherence amid increasingly virtual healthcare models.
  • Streamlined distribution and adaptive commercialization tactics across end-user environments are critical for ensuring timely access, calibrating market execution, and sustaining channel engagement.
  • Regional execution plans remain vital, as regulatory and reimbursement variability requires robust local strategies and strengthens the case for agile supply chains as a foundation for competitive position.
  • Integrated service models—blending therapy, monitoring, and patient support—can accelerate market entry and facilitate ongoing value creation over the product lifecycle.

Tariff Impact: Navigating Cost Pressures in Supply Chains

Recent tariff adjustments in the United States have increased supply chain complexity for MS therapies globally. Market participants have adapted by prioritizing nearshoring, multisource procurement, and stronger relationships with contract manufacturers, supporting continuity in drug access and reducing disruption risk. Heightened attention from payers and providers has driven robust cost-management efforts and accelerated the need for supply chain agility and flexible contracting to maintain operational effectiveness.

Methodology & Data Sources

This report synthesizes findings from peer-reviewed research, validated clinical guidelines, and publicly disclosed safety and efficacy data. Insights are strengthened by direct interviews with neurologists, pharmacists, payers, supply chain specialists, and pharmaceutical executives. Cross-verification ensures balanced analysis and connects clinical outcomes with commercial and policy perspectives.

Why This Report Matters

  • Delivers actionable segmentation and strategic recommendations for product development, market expansion, and portfolio stewardship within the Multiple Sclerosis Market.
  • Equips commercial and supply leaders with up-to-date guidance on payer strategy, leveraging digital health, and building resilient supply chains across global regions.
  • Enables senior decision-makers to prioritize investments and link innovation with operational delivery in complex healthcare environments.

By providing insights relevant to investment and execution, this report empowers organizations to align new technologies and therapies with evolving operational requirements across the healthcare system.

Conclusion

Ongoing advances in segmentation, system integration, and health technologies will continue to transform treatment delivery. Stakeholders who act on clinical insights and maintain operational agility are best positioned for sustainable advantage in the Multiple Sclerosis Market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Multiple Sclerosis Market, by Multiple Sclerosis Type
8.1. Primary Progressive
8.2. Relapsing Remitting
8.3. Secondary Progressive
9. Multiple Sclerosis Market, by Mechanism Of Action
9.1. Fumarate Therapies
9.2. Immunomodulators
9.2.1. Glatiramer Acetate
9.2.2. Interferons
9.3. Immunosuppressants
9.4. Monoclonal Antibodies
9.4.1. Alemtuzumab
9.4.2. Natalizumab
9.4.3. Ocrelizumab
9.4.4. Ofatumumab
9.5. Sphingosine 1 Phosphate Receptor Modulators
9.5.1. Fingolimod
9.5.2. Ozanimod
9.5.3. Ponesimod
9.5.4. Siponimod
10. Multiple Sclerosis Market, by Route Of Administration
10.1. Injectable
10.2. Intravenous
10.3. Oral
11. Multiple Sclerosis Market, by Distribution Channel
11.1. Hospital Pharmacies
11.2. Online Pharmacies
11.3. Retail Pharmacies
12. Multiple Sclerosis Market, by End User
12.1. Home Care Settings
12.2. Hospitals
12.3. Specialty Clinics
13. Multiple Sclerosis Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Multiple Sclerosis Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Multiple Sclerosis Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Multiple Sclerosis Market
17. China Multiple Sclerosis Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Bayer AG
18.6. Biogen Inc.
18.7. Bristol-Myers Squibb Company
18.8. Johnson & Johnson
18.9. Merck KGaA
18.10. Novartis AG
18.11. Pfizer Inc.
18.12. Roche Holding AG
18.13. Sanofi S.A.
18.14. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL MULTIPLE SCLEROSIS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL MULTIPLE SCLEROSIS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY PRIMARY PROGRESSIVE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY PRIMARY PROGRESSIVE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY PRIMARY PROGRESSIVE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY RELAPSING REMITTING, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY RELAPSING REMITTING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY RELAPSING REMITTING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SECONDARY PROGRESSIVE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SECONDARY PROGRESSIVE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SECONDARY PROGRESSIVE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GLATIRAMER ACETATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GLATIRAMER ACETATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GLATIRAMER ACETATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY INTERFERONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ALEMTUZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ALEMTUZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ALEMTUZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY NATALIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY NATALIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY NATALIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY OCRELIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY OCRELIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY OCRELIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY OFATUMUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY OFATUMUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY OFATUMUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 93. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
TABLE 94. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 95. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 96. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 97. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 98. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 99. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 100. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 101. NORTH AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. NORTH AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
TABLE 103. NORTH AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 104. NORTH AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 105. NORTH AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 106. NORTH AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 107. NORTH AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 108. NORTH AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 109. NORTH AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 110. LATIN AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. LATIN AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
TABLE 112. LATIN AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 113. LATIN AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 114. LATIN AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 115. LATIN AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 116. LATIN AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 117. LATIN AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 118. LATIN AMERICA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 128. EUROPE MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. EUROPE MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
TABLE 130. EUROPE MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 131. EUROPE MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 132. EUROPE MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 133. EUROPE MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 134. EUROPE MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 135. EUROPE MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 136. EUROPE MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 137. MIDDLE EAST MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 138. MIDDLE EAST MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
TABLE 139. MIDDLE EAST MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 140. MIDDLE EAST MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 141. MIDDLE EAST MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 142. MIDDLE EAST MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 143. MIDDLE EAST MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 144. MIDDLE EAST MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 145. MIDDLE EAST MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 146. AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 147. AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
TABLE 148. AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 149. AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 150. AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 151. AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 152. AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 153. AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 154. AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 158. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 159. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 160. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 161. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 162. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 163. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 164. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 165. ASEAN MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 166. ASEAN MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
TABLE 167. ASEAN MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 168. ASEAN MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 169. ASEAN MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 170. ASEAN MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 171. ASEAN MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 172. ASEAN MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 173. ASEAN MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 174. GCC MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 175. GCC MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
TABLE 176. GCC MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 177. GCC MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 178. GCC MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 179. GCC MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 180. GCC MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 181. GCC MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 182. GCC MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 183. EUROPEAN UNION MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 192. BRICS MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 193. BRICS MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
TABLE 194. BRICS MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 195. BRICS MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 196. BRICS MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 197. BRICS MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 198. BRICS MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 199. BRICS MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 200. BRICS MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 201. G7 MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 202. G7 MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
TABLE 203. G7 MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 204. G7 MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 205. G7 MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 206. G7 MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 207. G7 MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 208. G7 MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 209. G7 MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 210. NATO MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 211. NATO MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
TABLE 212. NATO MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 213. NATO MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 214. NATO MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 215. NATO MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 216. NATO MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 217. NATO MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 218. NATO MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 219. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 220. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 221. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
TABLE 222. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 223. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 224. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 225. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 226. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 227. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 228. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 229. CHINA MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 230. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2032 (USD MILLION)
TABLE 231. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 232. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 233. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 234. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 235. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 236. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 237. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Multiple Sclerosis market report include:
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages185
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 16.81 Billion
Forecasted Market Value ( USD ) by 2032 $ 23.14 Billion
Compound Annual Growth Rate5.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Oral Medications for Multiple Sclerosis Market - Global Forecast 2026-2032 - Product Image

Oral Medications for Multiple Sclerosis Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Multiple Sclerosis Drugs Market Report 2025 - Product Image

Multiple Sclerosis Drugs Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Multiple Sclerosis Therapeutics - Global Strategic Business Report - Product Image

Multiple Sclerosis Therapeutics - Global Strategic Business Report

  • Report
  • 268 Pages
  • Global
From
Multiple Sclerosis Treatment Global Market Report 2025 - Product Image

Multiple Sclerosis Treatment Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Relapsing Remitting Multiple Sclerosis Drug Pipeline Analysis Report 2025 - Product Image

Relapsing Remitting Multiple Sclerosis Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From

About the Multiple Sclerosis Drug Market

The Multiple Sclerosis (MS) Drug market is a subset of the Central Nervous System (CNS) Drugs market. MS is a chronic, progressive neurological disorder that affects the central nervous system, causing a wide range of physical and mental symptoms. MS drugs are used to reduce the frequency and severity of MS relapses, slow the progression of the disease, and improve the quality of life of those affected. MS drugs are typically divided into two categories: disease-modifying therapies (DMTs) and symptomatic therapies. DMTs are used to slow the progression of the disease, while symptomatic therapies are used to manage the symptoms of MS. Common DMTs include interferon beta, glatiramer acetate, fingolimod, and natalizumab. Common symptomatic therapies include muscle relaxants, antispasmodics, and antidepressants. The MS Drug market is highly competitive, with a number of major pharmaceutical companies competing for market share. Some of the major players in the market include Biogen, Novartis, Merck, Sanofi, and Teva Pharmaceuticals. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.